Premium Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasisPremium
Author(s)
Pereira Isabela A. G.,
Mendonça Débora V. C.,
Tavares Grasiele S. V.,
Lage Daniela P.,
Ramos Fernanda F.,
OliveiradaSilva João A.,
Antinarelli Luciana M. R.,
Machado Amanda S.,
Carvalho Lívia M.,
Carvalho Ana Maria R. S.,
Salustiano Iorrana V.,
Reis Thiago A. R.,
Bandeira Raquel S.,
Silva Alessandra M.,
Martins Vívian T.,
ChávezFumagalli Miguel A.,
Humbert Maria V.,
Roatt Bruno M.,
Duarte Mariana C.,
MenezesSouza Daniel,
Coimbra Elaine S.,
Leite João Paulo V.,
Coelho Eduardo A. F.,
Gonçalves Denise U.
Publication year2020
Publication title
parasite immunology
Resource typeJournals
PublisherWiley-Blackwell
Abstract Aims Treatment for visceral leishmaniasis (VL) is hampered by the toxicity and/or high cost of drugs, as well as by emergence of parasite resistance. Therefore, there is an urgent need for new antileishmanial agents. Methods and Results In this study, the antileishmanial activity of a diprenylated flavonoid called 5,7,3,4’‐tetrahydroxy‐6,8‐diprenylisoflavone (CMt) was tested against Leishmania infantum and L amazonensis species. Results showed that CMt presented selectivity index (SI) of 70.0 and 165.0 against L infantum and L amazonensis promastigotes, respectively, and of 181.9 and 397.8 against respective axenic amastigotes. Amphotericin B (AmpB) showed lower SI values of 9.1 and 11.1 against L infantum and L amazonensis promastigotes, respectively, and of 12.5 and 14.3 against amastigotes, respectively. CMt was effective in the treatment of infected macrophages and caused alterations in the parasite mitochondria. L infantum ‐infected mice treated with miltefosine, CMt alone or incorporated in polymeric micelles (CMt/Mic) presented significant reductions in the parasite load in distinct organs, when compared to the control groups. An antileishmanial Th1‐type cellular and humoral immune response were developed one and 15 days after treatment, with CMt/Mic‐treated mice presenting a better protective response. Conclusion Our data suggest that CMt/Mic could be evaluated as a chemotherapeutic agent against VL.
Subject(s)amastigote , amphotericin b , antifungal , biology , computer science , immune system , immunology , leishmania , leishmania infantum , leishmaniasis , microbiology and biotechnology , miltefosine , parasite hosting , parasite load , pharmacology , visceral leishmaniasis , world wide web
Language(s)English
SCImago Journal Rank0.795
H-Index75
eISSN1365-3024
pISSN0141-9838
DOI10.1111/pim.12784
Seeing content that should not be on Zendy? Contact us.